Tandem Diabetes Care Inc (TNDM)
Gross profit margin
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gross profit (ttm) | US$ in thousands | 367,690 | 389,918 | 404,590 | 404,801 | 412,987 | 411,193 | 403,513 | 394,021 | 376,215 | 353,042 | 321,610 | 283,546 | 260,520 | 230,236 | 215,606 | 211,120 | 194,212 | 175,475 | 146,588 | 111,771 |
Revenue (ttm) | US$ in thousands | 739,136 | 762,842 | 785,031 | 789,444 | 796,589 | 786,083 | 761,228 | 733,133 | 697,845 | 655,914 | 596,546 | 531,931 | 490,754 | 431,087 | 406,936 | 394,167 | 362,230 | 330,031 | 274,984 | 212,752 |
Gross profit margin | 49.75% | 51.11% | 51.54% | 51.28% | 51.84% | 52.31% | 53.01% | 53.74% | 53.91% | 53.82% | 53.91% | 53.31% | 53.09% | 53.41% | 52.98% | 53.56% | 53.62% | 53.17% | 53.31% | 52.54% |
December 31, 2023 calculation
Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $367,690K ÷ $739,136K
= 49.75%
The gross profit margin of Tandem Diabetes Care Inc has shown a downward trend over the past several quarters. The margin decreased from 53.41% in Q1 2022 to 49.17% in Q4 2023. This decline indicates that the company's cost of goods sold as a percentage of revenue has been increasing, affecting its overall profitability at the gross level. While the margin fluctuations are relatively small, management may need to closely monitor and potentially address any cost inefficiencies to maintain healthy profit margins in the future.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Tandem Diabetes Care Inc
TNDM
49.75%
3M Company
MMM
43.46%
Artivion Inc
AORT
69.22%
Baxter International Inc
BAX
33.34%
Becton Dickinson and Company
BDX
5.19%
Boston Scientific Corp
BSX
70.82%
DexCom Inc
DXCM
63.52%
Embecta Corp
EMBC
66.89%
Glaukos Corp
GKOS
78.86%
Globus Medical
GMED
65.05%
Haemonetics Corporation
HAE
26.64%